These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 29451369)
1. Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor. Collin MP; Lobell M; Hübsch W; Brohm D; Schirok H; Jautelat R; Lustig K; Bömer U; Vöhringer V; Héroult M; Grünewald S; Hess-Stumpp H ChemMedChem; 2018 Mar; 13(5):437-445. PubMed ID: 29451369 [TBL] [Abstract][Full Text] [Related]
2. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Grünewald S; Politz O; Bender S; Héroult M; Lustig K; Thuss U; Kneip C; Kopitz C; Zopf D; Collin MP; Boemer U; Ince S; Ellinghaus P; Mumberg D; Hess-Stumpp H; Ziegelbauer K Int J Cancer; 2019 Sep; 145(5):1346-1357. PubMed ID: 30807645 [TBL] [Abstract][Full Text] [Related]
3. Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor. Wu L; Zhang C; He C; Qian D; Lu L; Sun Y; Xu M; Zhuo J; Liu PCC; Klabe R; Wynn R; Covington M; Gallagher K; Leffet L; Bowman K; Diamond S; Koblish H; Zhang Y; Soloviev M; Hollis G; Burn TC; Scherle P; Yeleswaram S; Huber R; Yao W J Med Chem; 2021 Aug; 64(15):10666-10679. PubMed ID: 34269576 [TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Addeo A; Rothschild SI; Holer L; Schneider M; Waibel C; Haefliger S; Mark M; Fernandez E; Mach N; Mauti L; Jermann PM; Alborelli I; Calgua B; Savic-Prince S; Joerger M; Früh M Lung Cancer; 2022 Oct; 172():154-159. PubMed ID: 36099710 [TBL] [Abstract][Full Text] [Related]
5. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. Liu PCC; Koblish H; Wu L; Bowman K; Diamond S; DiMatteo D; Zhang Y; Hansbury M; Rupar M; Wen X; Collier P; Feldman P; Klabe R; Burke KA; Soloviev M; Gardiner C; He X; Volgina A; Covington M; Ruggeri B; Wynn R; Burn TC; Scherle P; Yeleswaram S; Yao W; Huber R; Hollis G PLoS One; 2020; 15(4):e0231877. PubMed ID: 32315352 [TBL] [Abstract][Full Text] [Related]
6. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors. Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155 [TBL] [Abstract][Full Text] [Related]
7. Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3). Yamani A; Zdżalik-Bielecka D; Lipner J; Stańczak A; Piórkowska N; Stańczak PS; Olejkowska P; Hucz-Kalitowska J; Magdycz M; Dzwonek K; Dubiel K; Lamparska-Przybysz M; Popiel D; Pieczykolan J; Wieczorek M Eur J Med Chem; 2021 Jan; 210():112990. PubMed ID: 33199155 [TBL] [Abstract][Full Text] [Related]
8. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156 [TBL] [Abstract][Full Text] [Related]
9. Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: design, synthesis, and biological activity. Chen Z; Wang X; Zhu W; Cao X; Tong L; Li H; Xie H; Xu Y; Tan S; Kuang D; Ding J; Qian X J Med Chem; 2011 Jun; 54(11):3732-45. PubMed ID: 21517068 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and preliminary biological evaluation of C-8 substituted guanine derivatives as small molecular inhibitors of FGFRs. Ye F; Chen L; Hu L; Xiao T; Yu S; Chen D; Wang Y; Liang G; Liu Z; Wang S Bioorg Med Chem Lett; 2015 Apr; 25(7):1556-60. PubMed ID: 25736993 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of N-phenylthieno[2,3-d]pyrimidin-4-amines as inhibitors of FGFR1. Gryshchenko AA; Bdzhola VG; Balanda AO; Briukhovetska NV; Kotey IM; Golub AG; Ruban TP; Lukash LL; Yarmoluk SM Bioorg Med Chem; 2015 May; 23(9):2287-93. PubMed ID: 25817240 [TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors. Zhang Z; Zhao D; Dai Y; Cheng M; Geng M; Shen J; Ma Y; Ai J; Xiong B Molecules; 2016 Oct; 21(10):. PubMed ID: 27782099 [TBL] [Abstract][Full Text] [Related]
14. Pemigatinib: First Approval. Hoy SM Drugs; 2020 Jun; 80(9):923-929. PubMed ID: 32472305 [TBL] [Abstract][Full Text] [Related]
15. An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors. Cheng W; Wang M; Tian X; Zhang X Eur J Med Chem; 2017 Jan; 126():476-490. PubMed ID: 27914362 [TBL] [Abstract][Full Text] [Related]
16. The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain. Skerratt SE; Andrews M; Bagal SK; Bilsland J; Brown D; Bungay PJ; Cole S; Gibson KR; Jones R; Morao I; Nedderman A; Omoto K; Robinson C; Ryckmans T; Skinner K; Stupple P; Waldron G J Med Chem; 2016 Nov; 59(22):10084-10099. PubMed ID: 27766865 [TBL] [Abstract][Full Text] [Related]
17. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors. Fan J; Dai Y; Shao J; Peng X; Wang C; Cao S; Zhao B; Ai J; Geng M; Duan W Bioorg Med Chem Lett; 2016 Jun; 26(11):2594-9. PubMed ID: 27117427 [TBL] [Abstract][Full Text] [Related]
19. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors. Pettus LH; Andrews KL; Booker SK; Chen J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS; Wang HL J Med Chem; 2016 Jul; 59(13):6407-30. PubMed ID: 27285051 [TBL] [Abstract][Full Text] [Related]
20. Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2. Ren L; Grina J; Moreno D; Blake JF; Gaudino JJ; Garrey R; Metcalf AT; Burkard M; Martinson M; Rasor K; Chen H; Dean B; Gould SE; Pacheco P; Shahidi-Latham S; Yin J; West K; Wang W; Moffat JG; Schwarz JB J Med Chem; 2015 Feb; 58(4):1976-91. PubMed ID: 25603482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]